SCHEMBL3002256

SCHEMBL3002256

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(C(C)(C)C)cc4)CC3)n2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.34
POLB P06746 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
GBA1 P04062 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM2B Q8NHM5 2/20 0.33
LMNA P02545 3/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPK1 P28482 1/20 0.33
KDM4A O75164 1/20 0.33
USP2 O75604 1/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
SIRT5 Q9NXA8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015108 0.93 AOC3 (0.35) ACHEHRH3GBA1AOC3HSD11B1
SCHEMBL3014372 0.92 GBA1 (0.41) ACHEPOLBHRH3GBA1KMT2A
SCHEMBL3011697 0.91 HSD11B1 (0.39) ACHEHRH3GBA1LMNAALDH1A1
SCHEMBL3012703 0.91 HTR2A (0.41) GBA1MEN1KMT2ALMNAALDH1A1
SCHEMBL3000391 0.90 KMT2A (0.37) HRH3MEN1KMT2ALMNAHTT
SCHEMBL3014690 0.90 HSD11B1 (0.41) SMN1; SMN2HSD11B1
SCHEMBL3017967 0.89 GBA1 (0.42) POLBHRH3GBA1MEN1KMT2A
SCHEMBL3010872 0.88 SMN1; SMN2 (0.41) HRH3KMT2ALMNAALDH1A1HTT
SCHEMBL3013175 0.88 HRH3 (0.34) HRH3GBA1MEN1KMT2ALMNA
SCHEMBL3012865 0.88 SMN1; SMN2 (0.38) HRH3GBA1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ACHE 2411/4885POLB 4649/4885HRH3 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.